Hemogenyx Historical Balance Sheet

HEMO Stock

343.40 20.90 6.48%

Trend analysis of Hemogenyx Pharmaceuticals PLC balance sheet accounts such as Net Debt of 1.8 M or Cash of 1.9 M provides information on Hemogenyx Pharmaceuticals' total assets, liabilities, and equity, which is the actual value of Hemogenyx Pharmaceuticals to its prevalent stockholders. By breaking down trends over time using Hemogenyx Pharmaceuticals balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Covid

Financial Statement Analysis is much more than just reviewing and examining Hemogenyx Pharmaceuticals latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Hemogenyx Pharmaceuticals is a good buy for the upcoming year.

Hemogenyx Pharmaceuticals Inventory

(77,715.91)

Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Hemogenyx Pharmaceuticals PLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

About Hemogenyx Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Hemogenyx Pharmaceuticals at a specified time, usually calculated after every quarter, six months, or one year. Hemogenyx Pharmaceuticals Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Hemogenyx Pharmaceuticals and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Hemogenyx currently owns. An asset can also be divided into two categories, current and non-current.

Hemogenyx Pharmaceuticals Balance Sheet Chart

At this time, Hemogenyx Pharmaceuticals' Other Assets are comparatively stable compared to the past year. Non Current Liabilities Total is likely to gain to about 2.8 M in 2024, whereas Total Stockholder Equity is likely to drop slightly above 2.1 M in 2024.

Total Assets Cash And Short Term Investments Common Stock Total Equity Common Stock Shares Outstanding Common Stock Non Currrent Assets Other

Add Fundamental

Total Assets

Total assets refers to the total amount of Hemogenyx Pharmaceuticals assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Hemogenyx Pharmaceuticals books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Cash And Short Term Investments

Short Term Investments is an account in the current assets section of Hemogenyx Pharmaceuticals balance sheet. This account contains Hemogenyx Pharmaceuticals investments that will expire within one year. These investments include stocks and bonds that can be liquidated by Hemogenyx Pharmaceuticals PLC fairly quickly. The sum of a company's cash on hand, including bank deposits and short-term, highly liquid investments that are easily convertible to known amounts of cash.

Common Stock Total Equity

The total value of common stock equity held by shareholders, representing their ownership interest in the company.

Common Stock Shares Outstanding

The total number of shares of a company's common stock that are currently owned by all its shareholders.

Non Currrent Assets Other

Assets that are not physical or tangible, expected to provide value for more than one year, and not easily converted into cash, such as long-term investments or patents.

Most accounts from Hemogenyx Pharmaceuticals' balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Hemogenyx Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Hemogenyx Pharmaceuticals PLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

	2021	2022	2023	2024 (projected)
Total Current Assets	7.1M	2.6M	2.2M	2.1M
Other Current Assets	298.2K	62.0K	922.0K	968.1K

Total Current Assets Other Current Assets

Hemogenyx Pharmaceuticals balance sheet Correlations

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Cash	Cash And Short Term Investments	Common Stock Total Equity	Common Stock Shares Outstanding	Other Current Assets	Total Current Assets	Common Stock	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Net Tangible Assets	Current Deferred Revenue	Accounts Payable	Non Current Assets Total	Other Assets	Non Current Liabilities Total	Other Stockholder Equity	Total Liab	Short Long Term Debt	Short Term Debt	Intangible Assets	Property Plant And Equipment Net
Total Assets		0.91	-0.38	-0.79	0.85	0.85	0.81	0.84	0.48	0.89	0.88	0.59	0.22	0.47	0.87	0.13	0.95	0.73	0.51	0.58	0.96	0.61	0.01	0.2	0.94	0.68
Total Stockholder Equity	0.91		-0.7	-0.59	0.96	0.96	0.61	0.63	0.37	0.97	0.71	0.21	0.21	0.26	0.75	0.06	0.76	0.47	0.4	0.26	0.87	0.26	-0.08	0.02	0.8	0.41
Net Debt	-0.38	-0.7		-0.14	-0.75	-0.75	-0.15	0.08	0.23	-0.71	-0.03	0.44	-0.16	0.08	-0.07	0.06	-0.13	0.3	0.03	0.47	-0.38	0.47	0.02	0.16	-0.16	0.35
Retained Earnings	-0.79	-0.59	-0.14		-0.5	-0.5	-0.71	-0.98	-0.84	-0.56	-0.97	-0.73	-0.14	-0.53	-0.94	-0.18	-0.85	-0.93	-0.6	-0.83	-0.81	-0.87	-0.04	-0.31	-0.88	-0.91
Cash	0.85	0.96	-0.75	-0.5		1.0	0.65	0.57	0.26	0.99	0.65	0.16	0.26	0.34	0.64	0.04	0.69	0.36	0.32	0.18	0.85	0.22	0.07	0.13	0.68	0.29
Cash And Short Term Investments	0.85	0.96	-0.75	-0.5	1.0		0.65	0.57	0.26	0.99	0.65	0.16	0.26	0.34	0.64	0.04	0.69	0.36	0.32	0.18	0.85	0.22	0.07	0.13	0.68	0.29
Common Stock Total Equity	0.81	0.61	-0.15	-0.71	0.65	0.65		0.77	0.43	0.69	0.81	0.73	0.44	0.66	0.65	0.21	0.77	0.59	0.46	0.55	0.84	0.67	0.27	0.43	0.71	0.53
Common Stock Shares Outstanding	0.84	0.63	0.08	-0.98	0.57	0.57	0.77		0.8	0.63	0.99	0.75	0.17	0.5	0.95	0.21	0.88	0.93	0.63	0.86	0.83	0.89	0.0	0.27	0.89	0.9
Other Current Assets	0.48	0.37	0.23	-0.84	0.26	0.26	0.43	0.8		0.35	0.78	0.44	0.15	0.27	0.79	0.03	0.51	0.74	0.41	0.66	0.47	0.65	-0.09	0.13	0.65	0.72
Total Current Assets	0.89	0.97	-0.71	-0.56	0.99	0.99	0.69	0.63	0.35		0.71	0.21	0.26	0.36	0.7	0.06	0.73	0.41	0.37	0.23	0.88	0.27	0.06	0.14	0.74	0.34
Common Stock	0.88	0.71	-0.03	-0.97	0.65	0.65	0.81	0.99	0.78	0.71		0.7	0.23	0.5	0.96	0.2	0.88	0.89	0.62	0.8	0.88	0.83	0.0	0.25	0.9	0.85
Short Long Term Debt Total	0.59	0.21	0.44	-0.73	0.16	0.16	0.73	0.75	0.44	0.21	0.7		0.25	0.6	0.62	0.18	0.73	0.81	0.43	0.83	0.57	0.91	0.15	0.4	0.65	0.8
Other Current Liab	0.22	0.21	-0.16	-0.14	0.26	0.26	0.44	0.17	0.15	0.26	0.23	0.25		0.13	0.16	-0.41	0.04	0.1	-0.31	0.04	0.22	0.07	-0.04	-0.02	0.15	0.05
Total Current Liabilities	0.47	0.26	0.08	-0.53	0.34	0.34	0.66	0.5	0.27	0.36	0.5	0.6	0.13		0.37	0.11	0.5	0.42	0.24	0.27	0.55	0.57	0.84	0.95	0.35	0.37
Net Tangible Assets	0.87	0.75	-0.07	-0.94	0.64	0.64	0.65	0.95	0.79	0.7	0.96	0.62	0.16	0.37		0.16	0.87	0.91	0.61	0.78	0.83	0.76	-0.14	0.12	0.93	0.89
Current Deferred Revenue	0.13	0.06	0.06	-0.18	0.04	0.04	0.21	0.21	0.03	0.06	0.2	0.18	-0.41	0.11	0.16		0.17	0.13	0.88	0.18	0.2	0.21	0.05	0.09	0.05	0.14
Accounts Payable	0.95	0.76	-0.13	-0.85	0.69	0.69	0.77	0.88	0.51	0.73	0.88	0.73	0.04	0.5	0.87	0.17		0.84	0.56	0.74	0.9	0.76	0.02	0.25	0.96	0.8
Non Current Assets Total	0.73	0.47	0.3	-0.93	0.36	0.36	0.59	0.93	0.74	0.41	0.89	0.81	0.1	0.42	0.91	0.13	0.84		0.55	0.93	0.68	0.93	-0.09	0.2	0.85	1.0
Other Assets	0.51	0.4	0.03	-0.6	0.32	0.32	0.46	0.63	0.41	0.37	0.62	0.43	-0.31	0.24	0.61	0.88	0.56	0.55		0.53	0.55	0.54	-0.04	0.12	0.49	0.55
Non Current Liabilities Total	0.58	0.26	0.47	-0.83	0.18	0.18	0.55	0.86	0.66	0.23	0.8	0.83	0.04	0.27	0.78	0.18	0.74	0.93	0.53		0.52	0.94	-0.23	0.07	0.73	0.94
Other Stockholder Equity	0.96	0.87	-0.38	-0.81	0.85	0.85	0.84	0.83	0.47	0.88	0.88	0.57	0.22	0.55	0.83	0.2	0.9	0.68	0.55	0.52		0.59	0.12	0.29	0.88	0.63
Total Liab	0.61	0.26	0.47	-0.87	0.22	0.22	0.67	0.89	0.65	0.27	0.83	0.91	0.07	0.57	0.76	0.21	0.76	0.93	0.54	0.94	0.59		0.11	0.4	0.7	0.92
Short Long Term Debt	0.01	-0.08	0.02	-0.04	0.07	0.07	0.27	0.0	-0.09	0.06	0.0	0.15	-0.04	0.84	-0.14	0.05	0.02	-0.09	-0.04	-0.23	0.12	0.11		0.95	-0.15	-0.14
Short Term Debt	0.2	0.02	0.16	-0.31	0.13	0.13	0.43	0.27	0.13	0.14	0.25	0.4	-0.02	0.95	0.12	0.09	0.25	0.2	0.12	0.07	0.29	0.4	0.95		0.08	0.16
Intangible Assets	0.94	0.8	-0.16	-0.88	0.68	0.68	0.71	0.89	0.65	0.74	0.9	0.65	0.15	0.35	0.93	0.05	0.96	0.85	0.49	0.73	0.88	0.7	-0.15	0.08		0.82
Property Plant And Equipment Net	0.68	0.41	0.35	-0.91	0.29	0.29	0.53	0.9	0.72	0.34	0.85	0.8	0.05	0.37	0.89	0.14	0.8	1.0	0.55	0.94	0.63	0.92	-0.14	0.16	0.82

Click cells to compare fundamentals

Hemogenyx Pharmaceuticals Account Relationship Matchups

Hemogenyx Pharmaceuticals balance sheet Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	1.0M	2.7M	8.5M	7.1M	6.1M	3.5M
Total Stockholder Equity	(346.5K)	890.8K	8.2M	3.3M	2.8M	2.1M
Net Debt	758.6K	(184.2K)	(6.8M)	890.1K	1.7M	1.8M
Retained Earnings	(6.0M)	(8.0M)	(13.1M)	(17.1M)	(23.8M)	(22.6M)
Cash	498.7K	1.8M	6.8M	2.5M	1.2M	1.9M
Cash And Short Term Investments	498.7K	1.8M	6.8M	2.5M	1.2M	1.9M
Common Stock Total Equity	3.6M	3.6M	3.6M	4.3M	5.0M	2.9M
Common Stock Shares Outstanding	360.7M	414.8M	774.0M	979.7M	1.1B	1.2B
Liabilities And Stockholders Equity	1.0M	2.7M	8.5M	7.1M	6.1M	3.5M
Other Current Assets	55.8K	105.0K	298.2K	62.0K	922.0K	968.1K
Total Current Assets	554.5K	1.9M	7.1M	2.6M	2.2M	2.1M
Common Stock	3.6M	3.6M	4.3M	9.8M	11.8M	12.3M
Short Long Term Debt Total	1.3M	1.6M	10.2K	3.4M	2.9M	1.5M
Other Current Liab	80.3K	47.5K	46.9K	51.9K	77.3K	71.2K
Total Current Liabilities	181.6K	1.8M	352.8K	748.4K	652.1K	526.2K
Net Tangible Assets	686.4K	(608.6K)	635.9K	7.8M	8.9M	9.4M
Accounts Payable	61.4K	113.2K	295.8K	374.3K	301.7K	154.9K
Non Current Assets Total	495.4K	747.3K	1.4M	4.5M	3.9M	4.1M
Non Current Liabilities Total	1.2M	10.0K	306.0K	3.1M	2.7M	2.8M
Other Stockholder Equity	7.7M	10.0M	23.0M	16.8M	14.9M	10.1M
Total Liab	1.4M	1.8M	352.8K	3.8M	3.3M	3.5M
Accumulated Other Comprehensive Income	452.5K	756.9K	878.3K	(58.8K)	1.1M	1.1M
Intangible Assets	272.8K	262.1K	255.0K	441.5K	470.2K	356.6K
Property Plant And Equipment Net	233.4K	268.7K	797.1K	3.9M	3.3M	3.5M
Non Currrent Assets Other	0.0	223.6K	142.6K	140.8K	153.7K	155.6K
Net Receivables	32.3K	56.3K	7.5K	9.8K	5.1K	4.9K
Property Plant Equipment	173.9K	233.4K	268.7K	797.1K	916.7K	962.5K
Net Invested Capital	797.6K	2.5M	8.2M	3.3M	2.8M	3.4M
Property Plant And Equipment Gross	233.4K	268.7K	1.1M	4.5M	4.0M	4.2M
Net Working Capital	372.9K	138.4K	6.8M	1.8M	1.5M	2.2M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

C	Citigroup
GM	General Motors
F	Ford Motor

Additional Tools for Hemogenyx Stock Analysis

When running Hemogenyx Pharmaceuticals' price analysis, check to measure Hemogenyx Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Hemogenyx Pharmaceuticals is operating at the current time. Most of Hemogenyx Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Hemogenyx Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Hemogenyx Pharmaceuticals' price. Additionally, you may evaluate how the addition of Hemogenyx Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC